



BioRx Receives URAC Specialty Pharmacy Accreditation

October 13, 2014



BioRx announced today that it has been awarded Specialty Pharmacy accreditation from URAC, a Washington, DC-based healthcare accrediting organization that establishes quality standards for the industry. BioRx is a highly specialized pharmacy and infusion services provider that secures necessary treatments for patients with ultra-orphan and rare, chronic diseases.

URAC's Specialty Pharmacy accreditation provides an external validation of excellence in specialty pharmacy management and provides continuous quality improvement processes that improve operations and enhance compliance. Specialty pharmaceuticals typically require special handling, administration, unique inventory management, and a high level of patient monitoring and support. URAC ensures that all stakeholders are represented in establishing meaningful quality measures supported by evidence-based practice for the entire healthcare industry.

"We are extremely proud to receive this accreditation from URAC," said Eric Hill, President and co-founder of BioRx. "Pursuing and achieving URAC accreditation, in addition to our current ACHC accreditation, exemplifies our ongoing commitment to meet standards of quality in everything we do. Ultimately, it creates an opportunity for us to continually improve and enhance our services."

BioRx maximizes therapeutic outcomes from select, high-cost specialty drugs. The company's portfolio includes a number of open-source and limited distribution therapies for hemophilia, primary immune deficiency, autoimmune disorders, hereditary angioedema, and alpha-1 antitrypsin deficiency. The company's clinical staff reaches patients and physicians in all 50 states.

To learn more about BioRx and its products and services, visit www.biorx.com.

About Symmetric Capital

Symmetric Capital, a private equity firm focused on profitable growth companies in the United States and Canada, invested in BioRx in 2010. With the flexibility to invest in either minority or majority ownership positions, Symmetric structures transactions that meet both the immediate and the longer-term objectives of owners and managers – all without changing a company's entrepreneurial culture or introducing excessive debt that restricts growth. Since 1990, Symmetric's principals have built dozens of successful, collaborative partnerships, beginning in each case with an equity investment to fund growth, shareholder liquidity, debt repayment, a management-led buyout or a strategic acquisition.

Symmetric targets companies with at least \$10 million in revenues and \$2 million in operating profits. Sectors of interest include business and financial services, healthcare, technology, software, education, and consumer and industrial products. With over \$200 million in committed capital under management, Symmetric typically invests \$5-25 million in each company. Larger transactions can be funded in conjunction with our limited partners or with other co-investors. For more information on Symmetric, please visit www.symmetriccapital.com.